Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK and Galapagos go separate ways on once-hyped anti-infective alliance

This article was originally published in Scrip

Executive Summary

It emerged at an R&D update provided by the Belgian biotech firm Galapagos this week that the potentially high-value anti-infectives alliance it established with GlaxoSmithKline in 2007 was dissolved last year. Galapagos took back rights to the antibacterial programmes and GSK retained those for the viral programmes in a split which Galapagos CEO Onno van de Stolpe said was prompted by Galapagos deciding that the costs of the alliance were unsustainable on its part.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts